[go: up one dir, main page]

SG10201500152UA - Abt-263 capsule - Google Patents

Abt-263 capsule

Info

Publication number
SG10201500152UA
SG10201500152UA SG10201500152UA SG10201500152UA SG10201500152UA SG 10201500152U A SG10201500152U A SG 10201500152UA SG 10201500152U A SG10201500152U A SG 10201500152UA SG 10201500152U A SG10201500152U A SG 10201500152UA SG 10201500152U A SG10201500152U A SG 10201500152UA
Authority
SG
Singapore
Prior art keywords
abt
capsule
Prior art date
Application number
SG10201500152UA
Other languages
English (en)
Inventor
Ping Tong
Deliang Zhou
Geoff G Z Zhang
Katherine Heemstra
Cristina M Fischer
Nathaniel Catron
Eric A Schmitt
Yeshwant D Sanzgiri
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of SG10201500152UA publication Critical patent/SG10201500152UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG10201500152UA 2009-12-22 2010-12-21 Abt-263 capsule SG10201500152UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28928909P 2009-12-22 2009-12-22

Publications (1)

Publication Number Publication Date
SG10201500152UA true SG10201500152UA (en) 2015-03-30

Family

ID=44187848

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201500152UA SG10201500152UA (en) 2009-12-22 2010-12-21 Abt-263 capsule
SG2012046876A SG181916A1 (en) 2009-12-22 2010-12-21 Abt-263 capsule

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012046876A SG181916A1 (en) 2009-12-22 2010-12-21 Abt-263 capsule

Country Status (16)

Country Link
US (1) US8927009B2 (fr)
EP (1) EP2515883A4 (fr)
JP (1) JP5779591B2 (fr)
KR (1) KR20120098915A (fr)
CN (1) CN102655858B (fr)
AU (1) AU2010336518B2 (fr)
BR (1) BR112012014499A2 (fr)
CA (1) CA2780177A1 (fr)
IL (1) IL219921A0 (fr)
MX (1) MX2012007325A (fr)
NZ (1) NZ599941A (fr)
RU (1) RU2550956C2 (fr)
SG (2) SG10201500152UA (fr)
TW (1) TWI508729B (fr)
WO (1) WO2011079127A1 (fr)
ZA (1) ZA201203627B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI471321B (zh) 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
ES2687705T3 (es) 2012-07-19 2018-10-26 Fujifilm Corporation Composición líquida que contiene un principio activo a base de taxano, proceso de producción de la misma y preparación medicinal líquida
CN102836160A (zh) * 2012-10-10 2012-12-26 武汉大学 一种治疗癌症的组合药物
SG11201600107RA (en) * 2013-07-08 2016-02-26 Abbvie Inc Stabilized pharmaceutical dosage forms comprising atrasentan
CN105916598B (zh) * 2014-01-21 2020-07-17 Bpsi控股有限责任公司 含有中链甘油酯的即释型膜包衣及用其包被的基质
EP3442584B1 (fr) * 2016-03-15 2021-07-28 Seagen Inc. Combinaisons de conjugués anticorps-médicament à base de pbd et d'inhibiteurs de bcl-2
TR201703149A2 (tr) * 2017-03-01 2018-09-21 Univ Yeditepe Kemoterapi̇k i̇laç kompozi̇syonu
PH12022551091A1 (en) 2019-11-05 2024-06-24 Abbvie Deutschland Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
WO1995014037A1 (fr) * 1993-11-17 1995-05-26 Ibah, Inc. Liquide transparent permettant l'administration de medicaments encapsules
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19929361A1 (de) 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US20020055631A1 (en) * 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
CZ20031902A3 (cs) * 2001-01-31 2004-07-14 Pfizer Products Inc. Etherové deriváty užitečné jako inhibitory isozymů PDE4
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
ES2343405T3 (es) * 2002-02-04 2010-07-30 Elan Pharma International Ltd. Composiciones nanoparticuladas que tienen lisozima como un estabilizador de superficie.
EP1480679B1 (fr) * 2002-02-26 2007-05-23 Astrazeneca AB Formulation pharmaceutique d'iressa comprenant un derive de cellulose soluble dans l'eau
AR038628A1 (es) * 2002-03-04 2005-01-19 Novartis Ag Composicion oftalmica
TWI262077B (en) * 2002-04-29 2006-09-21 Merck & Co Inc Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
EP2959893A1 (fr) * 2002-12-13 2015-12-30 DURECT Corporation Système d'administration de médicament par voie orale comprenant des matériaux de support liquides à viscosité élevée
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
WO2005049593A2 (fr) 2003-11-13 2005-06-02 Abbott Laboratories Promoteurs de l'apoptose contenant n-acylsulfonamide
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7790190B2 (en) * 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
CA2606147C (fr) 2005-05-12 2011-07-05 Abbott Laboratories Promoteurs d'apoptose
CN1706371B (zh) 2005-05-27 2010-11-10 沈阳药科大学 一种高效的马蔺子素制剂及其制备方法
CN101325944B (zh) 2005-10-11 2013-01-16 耶路撒冷希伯来大学伊萨姆研究开发公司 用于鼻部给药的组合物
EP1959926A1 (fr) * 2005-10-25 2008-08-27 Abbott Laboratories Preparation comprenant un medicament faiblement soluble dans l'eau et son procede d'utilisation
WO2007133796A2 (fr) * 2006-05-15 2007-11-22 Encysive Pharmaceuticals, Inc. Procédés et compositions de traitement de l'apnée du sommeil
EP1880715A1 (fr) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Composition de solubilisation acceptable sur le plan pharmaceutique et forme posologique contenant celle-ci
CN101534904B (zh) * 2006-09-05 2013-11-06 Abbvie公司 治疗血小板过量的bcl抑制剂
WO2008042216A2 (fr) * 2006-09-28 2008-04-10 Follica, Inc. PROCÉDÉS, matÉriel et compositions pour gÉNÉrer de nouveaux follicules pileux et faire pousser les cheveux
WO2008064116A2 (fr) * 2006-11-16 2008-05-29 Abbott Laboratories Procédé pour éviter ou traiter les rejets lors de transplantations d'organes, de cellules souches hématopoïétiques ou de moelle osseuse
WO2008124878A1 (fr) 2007-04-13 2008-10-23 Cryptopharma Pty Ltd Composés non stéroïdiens
CA2917512C (fr) * 2007-10-12 2025-08-05 President And Fellows Of Harvard College Nanotechnologie des vaccins
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
JP2011506338A (ja) * 2007-12-06 2011-03-03 アボット・ラボラトリーズ 癌の治療のためのａｂｔ−２６３の経口用組成物
CN101220008B (zh) 2008-01-21 2011-04-27 中国科学院广州生物医药与健康研究院 化合物abt-263的合成方法
US8168784B2 (en) * 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
DE102008040935A1 (de) * 2008-08-01 2010-02-04 BSH Bosch und Siemens Hausgeräte GmbH Küchengerät mit Motordrehzahlanzeige
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
RU2012101627A (ru) * 2009-06-18 2013-07-27 Эбботт Лэборетриз Стабильная суспензия лекарственного средства в виде наночастиц
KR20120085781A (ko) 2009-09-20 2012-08-01 아보트 러보러터리즈 Ｂｃｌ-２ 단백질 관련 질환을 치료하는데 사용하기 위한 ａｂｔ-２６３ 결정 형태 및 용매화물
CN101798292A (zh) 2010-03-29 2010-08-11 无锡好芳德药业有限公司 ABT-263衍生的新型Bcl-2蛋白抑制剂的制备

Also Published As

Publication number Publication date
KR20120098915A (ko) 2012-09-05
CN102655858A (zh) 2012-09-05
CN102655858B (zh) 2015-11-25
RU2550956C2 (ru) 2015-05-20
WO2011079127A1 (fr) 2011-06-30
AU2010336518B2 (en) 2014-03-06
SG181916A1 (en) 2012-08-30
CA2780177A1 (fr) 2011-06-30
IL219921A0 (en) 2012-07-31
ZA201203627B (en) 2013-01-30
RU2012131408A (ru) 2014-01-27
MX2012007325A (es) 2012-07-20
US8927009B2 (en) 2015-01-06
AU2010336518A1 (en) 2012-06-07
EP2515883A4 (fr) 2013-07-17
US20110159085A1 (en) 2011-06-30
EP2515883A1 (fr) 2012-10-31
NZ599941A (en) 2014-06-27
BR112012014499A2 (pt) 2016-08-16
JP5779591B2 (ja) 2015-09-16
TWI508729B (zh) 2015-11-21
JP2013515078A (ja) 2013-05-02
TW201130493A (en) 2011-09-16

Similar Documents

Publication Publication Date Title
PT2391559E (pt) Cápsula contendo uma dose
IL219087A0 (en) Benzimidazole-imidazole derivatives
IL217956A0 (en) N1-sulfonyl-5-fluoropyrimidinone derivatives
IL217953A0 (en) 5-fluoropyrimidinone derivatives
IL216007A0 (en) Isoxazole-pyridine derivatives
PL2448439T3 (pl) Trykot
IL215109A0 (en) Isoxazole-pyridazine derivatives
ZA201106855B (en) Oxasiazole derivatives
IL214941A0 (en) Isoxazole-pyrazole derivatives
EP2413177A4 (fr) Endoscope à capsule
ZA201200813B (en) N1-substituted-5-fluoro-2-oxopyrimidinone-1-(2h)-carboxamide derivatives
IL217952A0 (en) N1-acyl-5-fluoropyrimidinone derivatives
IL213927A0 (en) Deoxyactagardine derivatives
IL216761A0 (en) Pyrazinooxazepine derivatives
IL219921A0 (en) Abt-263 capsule
GB0904624D0 (en) Gas capsule
GB2471453B (en) Fragrance capsule
GB0921967D0 (en) Novel Aryloxyanilide Derivatives
ZA201104279B (en) Tetrahydronaphthalen-2-ol derivatives
GB0912499D0 (en) Indopyl-pyridone derivatives
HK1177146A (zh) Abt-263膠囊
PH32008000447S1 (en) Capsule bed
GB0903349D0 (en) Concept four
AU324165S (en) Coffee capsule